Find out more about CHONQUER

Do you have patients with chondrosarcoma in your care?

The CHONQUER study is a Phase III, randomized, double-blind clinical trial evaluating the safety and effectiveness of an investigational treatment for adults with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation. This mutation is present in approximately 50% of conventional chondrosarcomas.

Conventional chondrosarcoma is the most common primary bone sarcoma in adults. However, current treatment options are very limited, as conventional chondrosarcoma tumors can resist chemotherapy. Surgery is the main approach for localized diseases, but many patients with advanced or metastatic chondrosarcoma have no systemic treatment options. There is a critical need for new therapies to address this challenging condition.

Participants will take the investigational treatment or a placebo orally once daily until disease progression or treatment discontinuation. Once a participant starts on the treatment, the purpose is to continue until their disease really worsens or in case too many side effects are encountered. After treatment ends, follow-up visits will be scheduled to monitor the health of the participants. Throughout the study, participants will attend regular visits to monitor their health and undergo necessary assessments.

This study represents an important opportunity to explore potential new therapies for patients with limited options. If you have patients who meet the eligibility criteria, consider referring them to the CHONQUER study.

Participants may be eligible under these criteria:

Have documented disease progression or recurrence within 12 months.
Have received no more than one prior systemic treatment (chemotherapy / targeted or other treatment) for advanced/metastatic chondrosarcoma.
Have a measurable disease at baseline on the scan
Have an ECOG score 0-1 (i.e. Fully active or restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).

If you have patients who meet these criteria and you think they may be interested in this study, or if you have a patient you would like to refer, please contact the nearest clinical site:

Participants may not be eligible under these criteria:

Unable to swallow oral medication.
Previously treated with an IDH1 inhibitor.
Had a major surgery in the past 4 weeks.
Have significant active cardiac disease within 6 months prior to randomization, including New York Heart Association (NYHA) Class III or IV congestive heart failure; myocardial infarction; unstable angina; and/or stroke.
Are pregnant or breastfeeding

Find out more information about the CHONQUER study here.